New Risk • May 28
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.3% Last year net profit margin: 2.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 50% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (1.3% net profit margin). Market cap is less than US$100m (฿344.8m market cap, or US$10.6m). Valuation Update With 7 Day Price Move • May 13
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to ฿1.32, the stock trades at a trailing P/E ratio of 36.8x. Average trailing P/E is 9x in the Chemicals industry in Thailand. Total loss to shareholders of 41% over the past three years. Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ฿1.24, the stock trades at a trailing P/E ratio of 34.6x. Average trailing P/E is 9x in the Chemicals industry in Thailand. Total loss to shareholders of 58% over the past three years. New Risk • Mar 02
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 425% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 50% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.3% net profit margin). Market cap is less than US$100m (฿347.7m market cap, or US$11.1m). Reported Earnings • Mar 02
Full year 2025 earnings released: EPS: ฿0.037 (vs ฿0.077 in FY 2024) Full year 2025 results: EPS: ฿0.037 (down from ฿0.077 in FY 2024). Revenue: ฿815.8m (down 9.8% from FY 2024). Net income: ฿10.5m (down 53% from FY 2024). Profit margin: 1.3% (down from 2.4% in FY 2024). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. New Risk • Feb 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Thai stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 57% per year over the past 5 years. Minor Risk Market cap is less than US$100m (฿342.0m market cap, or US$11.0m). Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to ฿1.20, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 12x in the Chemicals industry in Thailand. Total loss to shareholders of 65% over the past three years. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ฿1.05, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 12x in the Chemicals industry in Thailand. Total loss to shareholders of 72% over the past three years. New Risk • Jan 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Thai stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 57% per year over the past 5 years. Market cap is less than US$10m (฿293.5m market cap, or US$9.32m). Minor Risk Share price has been volatile over the past 3 months (6.4% average weekly change). Reported Earnings • Nov 12
Third quarter 2025 earnings released: EPS: ฿0.02 (vs ฿0.081 loss in 3Q 2024) Third quarter 2025 results: EPS: ฿0.02 (up from ฿0.081 loss in 3Q 2024). Revenue: ฿201.8m (down 10% from 3Q 2024). Net income: ฿5.83m (up ฿29.0m from 3Q 2024). Profit margin: 2.9% (up from net loss in 3Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. New Risk • Oct 14
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ฿316.3m (US$9.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 61% per year over the past 5 years. Market cap is less than US$10m (฿316.3m market cap, or US$9.65m). Reported Earnings • Aug 16
Second quarter 2025 earnings released: ฿0.04 loss per share (vs ฿0.016 profit in 2Q 2024) Second quarter 2025 results: ฿0.04 loss per share (down from ฿0.016 profit in 2Q 2024). Revenue: ฿195.5m (down 10% from 2Q 2024). Net loss: ฿11.7m (down 355% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Announcement • Aug 16
Ubis (Asia) Public Company Limited (SET:UBIS) entered into a share purchase agreement to acquire an additional 77% stake in Thai Top Coat Group Company Limited from Big.M.J.Trade Company Limited for THB 51.1 million. Ubis (Asia) Public Company Limited (SET:UBIS) entered into a share purchase agreement to acquire an additional 77% stake in Thai Top Coat Group Company Limited from Big.M.J.Trade Company Limited for THB 51.1 million on August 14, 2025. A cash consideration of THB 51.13 million valued at THB 830 per share will be paid by Ubis (Asia) Public Company Limited. As part of consideration, THB 51.13 million is paid towards common equity of Thai Top Coat Group Company Limited. Upon completion, Ubis (Asia) Public Company Limited will own 87% stake in Thai Top Coat Group Company Limited. In a related transaction, Ubis (Asia) Public Company Limited agreed to acquire 74.5% stake in Kame Chemical Can Company Limited. The transaction will be financed through operating cash flows.
The transaction is subject to approval of merger agreement by the board and shareholders of Big.M.J.Trade Company Limited and approval of offer by the board Ubis (Asia) Public Company Limited. The deal has been approved by the board Ubis (Asia) Public Company Limited. The expected completion of the transaction is within September 13, 2025. Reported Earnings • May 09
First quarter 2025 earnings released: EPS: ฿0.01 (vs ฿0.079 in 1Q 2024) First quarter 2025 results: EPS: ฿0.01 (down from ฿0.079 in 1Q 2024). Revenue: ฿192.1m (down 14% from 1Q 2024). Net income: ฿3.73m (down 84% from 1Q 2024). Profit margin: 1.9% (down from 10% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 27
Full year 2024 earnings released: EPS: ฿0.08 (vs ฿0.26 loss in FY 2023) Full year 2024 results: EPS: ฿0.08 (up from ฿0.26 loss in FY 2023). Revenue: ฿904.1m (up 1.8% from FY 2023). Net income: ฿22.0m (up ฿95.8m from FY 2023). Profit margin: 2.4% (up from net loss in FY 2023). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 37% per year, which means it has not declined as severely as earnings. Announcement • Feb 26
Ubis (Asia) Public Company Limited, Annual General Meeting, Apr 23, 2025 Ubis (Asia) Public Company Limited, Annual General Meeting, Apr 23, 2025, at 10:00 SE Asia Standard Time. New Risk • Feb 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ฿330.6m (US$9.84m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (฿330.6m market cap, or US$9.84m). Reported Earnings • Nov 13
Third quarter 2024 earnings released: ฿0.08 loss per share (vs ฿0.09 loss in 3Q 2023) Third quarter 2024 results: ฿0.08 loss per share (improved from ฿0.09 loss in 3Q 2023). Revenue: ฿224.6m (flat on 3Q 2023). Net loss: ฿23.2m (loss narrowed 10.0% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 14
Second quarter 2024 earnings released: EPS: ฿0.02 (vs ฿0.064 loss in 2Q 2023) Second quarter 2024 results: EPS: ฿0.02 (up from ฿0.064 loss in 2Q 2023). Revenue: ฿217.6m (down 17% from 2Q 2023). Net income: ฿4.59m (up ฿22.8m from 2Q 2023). Profit margin: 2.1% (up from net loss in 2Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Somchai Wongsabsin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 16
First quarter 2024 earnings released: EPS: ฿0.08 (vs ฿0.061 loss in 1Q 2023) First quarter 2024 results: EPS: ฿0.08 (up from ฿0.061 loss in 1Q 2023). Revenue: ฿222.8m (up 13% from 1Q 2023). Net income: ฿22.5m (up ฿39.9m from 1Q 2023). Profit margin: 10% (up from net loss in 1Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance. New Risk • Apr 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Thai stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 55% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (฿541.5m market cap, or US$14.6m). Announcement • Feb 28
Ubis (Asia) Public Company Limited, Annual General Meeting, Apr 26, 2024 Ubis (Asia) Public Company Limited, Annual General Meeting, Apr 26, 2024, at 10:00 SE Asia Standard Time. Agenda: To Consider and acknowledge the Minutes of the Annual General Meeting of Shareholders No. 1/2023; to Consider and acknowledge the operational results for the year 2023; to consider and approve the financial statements of the Company for the year 2023, ending on December 31, 2023; to Consider and approve the omission of dividend payment for the operational results of the year 2023; to Consider and approve the election of directors to replace the directors who retired by rotation for the year 2024; to Consider and approve the determination of the directors' remuneration for the year 2024; to consider and approve the auditor and audit fees for the year 2024; and to discuss other matters. Reported Earnings • Feb 28
Full year 2023 earnings released: ฿0.26 loss per share (vs ฿0.072 loss in FY 2022) Full year 2023 results: ฿0.26 loss per share (further deteriorated from ฿0.072 loss in FY 2022). Revenue: ฿888.3m (down 15% from FY 2022). Net loss: ฿73.8m (loss widened 267% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance. New Risk • Nov 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Thai stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (฿510.1m market cap, or US$14.6m). Reported Earnings • Nov 17
Third quarter 2023 earnings released: ฿0.09 loss per share (vs ฿0.074 profit in 3Q 2022) Third quarter 2023 results: ฿0.09 loss per share (down from ฿0.074 profit in 3Q 2022). Revenue: ฿225.9m (down 19% from 3Q 2022). Net loss: ฿25.7m (down 222% from profit in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 11
Second quarter 2023 earnings released: ฿0.06 loss per share (vs ฿0.031 profit in 2Q 2022) Second quarter 2023 results: ฿0.06 loss per share (down from ฿0.031 profit in 2Q 2022). Revenue: ฿262.4m (down 3.3% from 2Q 2022). Net loss: ฿18.2m (down 307% from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Somchai Wongsabsin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 15
Second quarter 2022 earnings released: EPS: ฿0.03 (vs ฿0.14 in 2Q 2021) Second quarter 2022 results: EPS: ฿0.03 (down from ฿0.14 in 2Q 2021). Revenue: ฿271.3m (down 18% from 2Q 2021). Net income: ฿8.80m (down 73% from 2Q 2021). Profit margin: 3.2% (down from 9.9% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Reported Earnings • May 19
First quarter 2022 earnings released: ฿0.03 loss per share (vs ฿0.089 profit in 1Q 2021) First quarter 2022 results: ฿0.03 loss per share (down from ฿0.089 profit in 1Q 2021). Revenue: ฿264.1m (down 2.8% from 1Q 2021). Net loss: ฿8.40m (down 142% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Board Change • Apr 27
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Somchai Wongsabsin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improved over the past week After last week's 16% share price gain to ฿5.95, the stock trades at a trailing P/E ratio of 31x. Average trailing P/E is 14x in the Chemicals industry in Thailand. Total returns to shareholders of 18% over the past three years. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improved over the past week After last week's 32% share price gain to ฿5.80, the stock trades at a trailing P/E ratio of 30.2x. Average trailing P/E is 14x in the Chemicals industry in Thailand. Total returns to shareholders of 14% over the past three years. Reported Earnings • Mar 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: ฿0.24 (down from ฿0.53 in FY 2020). Revenue: ฿1.16b (up 13% from FY 2020). Net income: ฿54.7m (down 54% from FY 2020). Profit margin: 4.7% (down from 12% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Buying Opportunity • Jan 27
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 22%. The fair value is estimated to be ฿7.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.9% per annum over the last 3 years. Earnings per share has declined by 9.4% per annum over the last 3 years. Reported Earnings • Nov 18
Third quarter 2021 earnings released: EPS ฿0.05 (vs ฿0.22 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ฿286.0m (up 7.1% from 3Q 2020). Net income: ฿11.5m (down 77% from 3Q 2020). Profit margin: 4.0% (down from 19% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Upcoming Dividend • Oct 26
Upcoming dividend of ฿0.20 per share Eligible shareholders must have bought the stock before 02 November 2021. Payment date: 18 November 2021. Trailing yield: 6.0%. Within top quartile of Thai dividend payers (4.7%). Higher than average of industry peers (2.4%). Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment improved over the past week After last week's 22% share price gain to ฿17.40, the stock trades at a trailing P/E ratio of 36.3x. Average trailing P/E is 14x in the Chemicals industry in Thailand. Total returns to shareholders of 309% over the past three years. Valuation Update With 7 Day Price Move • Sep 09
Investor sentiment improved over the past week After last week's 33% share price gain to ฿9.60, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 13x in the Chemicals industry in Thailand. Total returns to shareholders of 132% over the past three years. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS ฿0.14 (vs ฿0.13 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: ฿330.6m (up 29% from 2Q 2020). Net income: ฿32.8m (up 7.1% from 2Q 2020). Profit margin: 9.9% (down from 12% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Executive Departure • Jul 13
Deputy Managing Director of Finance, Accounting & IT and Company Secretary Supat Turatunmanon has left the company On the 30th of June, Supat Turatunmanon's tenure as Deputy Managing Director of Finance, Accounting & IT and Company Secretary ended. We don't have any record of a personal shareholding under Supat's name. A total of 6 executives have left over the last 12 months. Executive Departure • May 27
Independent Director has left the company On the 14th of May, Kavin Chalermroj's tenure as Independent Director ended after 3.9 years in the role. We don't have any record of a personal shareholding under Kavin's name. A total of 9 executives have left over the last 12 months. Executive Departure • May 26
Independent Director has left the company On the 14th of May, Anant Sirisaengtaksin's tenure as Independent Director ended after 4.0 years in the role. We don't have any record of a personal shareholding under Anant's name. A total of 8 executives have left over the last 12 months. Reported Earnings • May 19
First quarter 2021 earnings released: EPS ฿0.09 (vs ฿0.14 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: ฿271.7m (up 28% from 1Q 2020). Net income: ฿20.3m (down 39% from 1Q 2020). Profit margin: 7.5% (down from 16% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Executive Departure • May 08
MD & Director has left the company On the 30th of April, Pasithphol Temritikulchai's tenure as MD & Director ended after less than a year in the role. We don't have any record of a personal shareholding under Pasithphol's name. A total of 7 executives have left over the last 12 months. Executive Departure • May 08
Director has left the company On the 30th of April, Kittisak Phanunanon's tenure as Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Kittisak's name. A total of 7 executives have left over the last 12 months. Upcoming Dividend • Apr 21
Upcoming dividend of ฿0.25 per share Eligible shareholders must have bought the stock before 28 April 2021. Payment date: 18 May 2021. Trailing yield: 6.2%. Within top quartile of Thai dividend payers (4.9%). Higher than average of industry peers (1.9%). Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improved over the past week After last week's 16% share price gain to ฿7.05, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 20x in the Chemicals industry in Thailand. Total returns to shareholders of 58% over the past three years. Reported Earnings • Feb 20
Full year 2020 earnings released: EPS ฿0.53 (vs ฿0.47 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: ฿1.02b (up 12% from FY 2019). Net income: ฿120.0m (up 13% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 21
New 90-day high: ฿5.75 The company is up 15% from its price of ฿5.00 on 22 October 2020. The Thai market is up 26% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 48% over the same period. Is New 90 Day High Low • Dec 18
New 90-day high: ฿5.60 The company is up 12% from its price of ฿5.00 on 18 September 2020. The Thai market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 35% over the same period. Reported Earnings • Nov 13
Third quarter 2020 earnings released: EPS ฿0.22 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ฿267.0m (up 19% from 3Q 2019). Net income: ฿50.9m (up 80% from 3Q 2019). Profit margin: 19% (up from 13% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Nov 12
New 90-day high: ฿5.45 The company is up 18% from its price of ฿4.62 on 14 August 2020. The Thai market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period. 
